Primary Hyperoxaluria Type 1
Invitae and Alnylam have partnered to offer genetic testing at no charge for individuals who may carry a gene mutation known to be associated with primary hyperoxaluria type 1.
The Alnylam Act program was created to potentially enable diagnosis and to provide genetic counseling to help people make more informed decisions about their health.
Unlock the underlying cause of CKD with genetic testing. Reata Pharmaceuticals and Invitae have partnered to offer sponsored, no-charge genetic testing and counseling for patients with chronik kidney disease (CKD) to facilitate diagnosis of several rare forms of CKD, including Alport syndrome, FSGS, and one form of ADPKD (PKD2).
By providing precise genetic information, KIDNEYCODE can help guide important, often time-sensitive health decisions for patients at risk for progressive CKD.
Estimate your out-of-pocket cost for Invitae tests related to a personal or family history of breast, ovarian, colorectal, or uterine cancer.
The amount shown above is an estimate of your out-of-pocket cost based upon the information you entered about your health insurance coverage. It is not a confirmation that the test has been authorized by your insurance provider. Your final cost may vary based upon your health plan design, deductible, co-insurance, and out-of-pocket limits. Learn More >
As part of Invitae’s dedication to making high-quality genetic testing affordable and accessible, we also offer a patient pre-pay option of $250. Learn More >
We could not determine an out-of-pocket estimate. Please contact us for assistance.